OBJECTIVE: To estimate risk factors associated with long-term outcome (i.e., 1-year survival) in patients with Staphylococcus aureus bacteremia (SAB). METHODS AND MATERIALS: This was a retrospective study in which the microbiological laboratory data records of patients admitted to the University Hospital of Regensburg between January 2004 and June 2005 were examined to identify those patients with blood cultures positive for S. aureus. Corresponding clinical records for all patients were reviewed using a standardized questionnaire. Of the 119 patients identified with SAB, 80 were available for the >1-year follow-up. RESULTS: Crude 1-year mortality was 47.5; 30- and 90-day mortality was 28.8 and 37.5%, respectively. In-hospital mortality was 28.8%. There were no significant differences in 1-year survival in terms of age, gender, antibiotic resistance, and mode of acquisition (nosocomial vs. community-acquired). A significantly better survival was observed with an identifiable focus present, if the chosen empiric antibiotic therapy was adequate or if the body mass index of the patient was >24. CONCLUSION: In summary, in this patient cohort, considerable additional mortality due to SAB beyond 30 or 90 days was present. Our results suggest that long-term survival data should be taken into account in outcome studies involving patients with S. aureus bacteremia.
OBJECTIVE: To estimate risk factors associated with long-term outcome (i.e., 1-year survival) in patients with Staphylococcus aureus bacteremia (SAB). METHODS AND MATERIALS: This was a retrospective study in which the microbiological laboratory data records of patients admitted to the University Hospital of Regensburg between January 2004 and June 2005 were examined to identify those patients with blood cultures positive for S. aureus. Corresponding clinical records for all patients were reviewed using a standardized questionnaire. Of the 119 patients identified with SAB, 80 were available for the >1-year follow-up. RESULTS: Crude 1-year mortality was 47.5; 30- and 90-day mortality was 28.8 and 37.5%, respectively. In-hospital mortality was 28.8%. There were no significant differences in 1-year survival in terms of age, gender, antibiotic resistance, and mode of acquisition (nosocomial vs. community-acquired). A significantly better survival was observed with an identifiable focus present, if the chosen empiric antibiotic therapy was adequate or if the body mass index of the patient was >24. CONCLUSION: In summary, in this patient cohort, considerable additional mortality due to SAB beyond 30 or 90 days was present. Our results suggest that long-term survival data should be taken into account in outcome studies involving patients with S. aureus bacteremia.
Authors: J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey Journal: Clin Infect Dis Date: 2000-04-03 Impact factor: 9.079
Authors: Bettina Wurzinger; Martin W Dünser; Christoph Wohlmuth; Martina C Deutinger; Hanno Ulmer; Christian Torgersen; Christian A Schmittinger; Wilhelm Grander; Walter R Hasibeder Journal: Wien Klin Wochenschr Date: 2010-01 Impact factor: 1.704
Authors: Charles W Hogue; Joshua D Stearns; Elizabeth Colantuoni; Karen A Robinson; Tracey Stierer; Nanhi Mitter; Peter J Pronovost; Dale M Needham Journal: Intensive Care Med Date: 2009-02-03 Impact factor: 17.440
Authors: Robert L Smith; Tae W Chong; Traci L Hedrick; Michael G Hughes; Heather L Evans; Shannon T McElearney; Timothy L Pruett; Robert G Sawyer Journal: Surg Infect (Larchmt) Date: 2007-12 Impact factor: 2.150
Authors: D Yahav; S Yassin; H Shaked; E Goldberg; J Bishara; M Paul; L Leibovici Journal: Eur J Clin Microbiol Infect Dis Date: 2016-02-12 Impact factor: 3.267
Authors: Miguel A Chavez; Satish Munigala; Carey-Ann D Burnham; Melanie L Yarbrough; David K Warren Journal: J Clin Microbiol Date: 2022-03-16 Impact factor: 11.677
Authors: Johannes P Borde; Nadide Batin; Siegbert Rieg; Rüdiger Feik; Christian Reimling; Winfried V Kern; Katja de With; Johannes Hübner; Michaela Ruhnke; Klaus Kaier Journal: Infection Date: 2014-06-03 Impact factor: 3.553
Authors: Julie Paulsen; Arne Mehl; Åsa Askim; Erik Solligård; Bjørn Olav Åsvold; Jan Kristian Damås Journal: BMC Infect Dis Date: 2015-03-04 Impact factor: 3.090
Authors: Kim O Gradel; Ulrich S Jensen; Henrik C Schønheyder; Christian Østergaard; Jenny D Knudsen; Sonja Wehberg; Mette Søgaard Journal: BMC Infect Dis Date: 2017-02-06 Impact factor: 3.090